These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 16355501)

  • 41. Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption.
    Sølling AS; Harsløf T; Jørgensen NR; Langdahl B
    Osteoporos Int; 2023 Mar; 34(3):599-605. PubMed ID: 36543965
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
    Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
    Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.
    Hannon R; Blumsohn A; Naylor K; Eastell R
    J Bone Miner Res; 1998 Jul; 13(7):1124-33. PubMed ID: 9661076
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients.
    Chao TY; Yu JC; Ku CH; Chen MM; Lee SH; Janckila AJ; Yam LT
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):544-50. PubMed ID: 15701839
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
    Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients.
    Ueda M; Inaba M; Okuno S; Nagasue K; Kitatani K; Ishimura E; Shimizu M; Miki T; Kim M; Nishizawa Y
    Am J Kidney Dis; 2002 Oct; 40(4):802-9. PubMed ID: 12324916
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy.
    Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Pons F; Martínez de Osaba MJ; Echevarría M; Ballesta AM; Muñoz-Gómez J
    Bone; 1999 Sep; 25(3):349-53. PubMed ID: 10495139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
    Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
    Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis.
    Michalská D; Stepan JJ; Basson BR; Pavo I
    J Clin Endocrinol Metab; 2006 Mar; 91(3):870-7. PubMed ID: 16352692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.
    Bauer DC; Garnero P; Hochberg MC; Santora A; Delmas P; Ewing SK; Black DM;
    J Bone Miner Res; 2006 Feb; 21(2):292-9. PubMed ID: 16418785
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared.
    Bettica P; Bevilacqua M; Vago T; Masino M; Cucinotta E; Norbiato G
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3034-9. PubMed ID: 9284739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in bone mass and bone turnover following ankle fracture.
    Ingle BM; Hay SM; Bottjer HM; Eastell R
    Osteoporos Int; 1999; 10(5):408-15. PubMed ID: 10591839
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
    Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
    JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial.
    Fahrleitner-Pammer A; Piswanger-Soelkner JC; Pieber TR; Obermayer-Pietsch BM; Pilz S; Dimai HP; Prenner G; Tscheliessnigg KH; Hauge E; Portugaller RH; Dobnig H
    J Bone Miner Res; 2009 Jul; 24(7):1335-44. PubMed ID: 19257824
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Abnormal bone mineral density and bone turnover marker expression profiles in patients with primary spontaneous pneumothorax.
    Yu L; Li H; Hou S; Hu B; Zhao L; Miao J; Wang Y; Li T; Zhang Z; You B; Pang B; Liang Y; Zhao Y; Hao W
    J Thorac Dis; 2016 Jun; 8(6):1188-96. PubMed ID: 27293836
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PINP as an aid for monitoring patients treated with teriparatide.
    Tsujimoto M; Chen P; Miyauchi A; Sowa H; Krege JH
    Bone; 2011 Apr; 48(4):798-803. PubMed ID: 21168536
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Development for the determination of band 5b tartrate-resistant acid phosphatase activity in serum].
    Uchida K; Nakanishi M; Yoh K
    Rinsho Byori; 2001 Jan; 49(1):51-5. PubMed ID: 11215484
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
    Tankó LB; Bagger YZ; Alexandersen P; Devogelaer JP; Reginster JY; Chick R; Olson M; Benmammar H; Mindeholm L; Azria M; Christiansen C
    J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.